Pfizer’s breast cancer drug is too expensive, British agency said

News Hour:

Pfizer’s breast cancer drug Ibrance, or palbociclib, is too expensive to justify its use on Britain’s state-run health service, the country’s healthcare cost-effectiveness watchdog said on Friday.

The National Institute for Health and Care Excellence (NICE) said in draft guidance that although the medicine was likely to offer some improvement in overall survival, this could not be quantified from clinical trials, reports Reuters.

“Even when allowing for these potential benefits, it was still not enough to make palbociclib cost-effective at its current price,” Carole Longson, director of NICE’s center for health technology assessment, said in a statement on Friday.

The logo of Dow Jones Industrial Average stock market index listed company Pfizer is pictured here in La Jolla, California

Ibrance’s list price is 2,950 pounds ($3,700) per 28 days. Pfizer UK’s oncology head David Montgomery noted that the NICE decision was not final decision and said the U.S. drugmaker was committed to working to try and find a solution to make the drug available.

Avatar

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Advertisement

News of the Month

February 2017
S M T W T F S
« Jan   Mar »
 1234
567891011
12131415161718
19202122232425
262728  
Scroll Up
%d bloggers like this: